Discover
Viaskin Peanut (DBV 712) / DBV TechnologiesDBV Technologies Announces Publication of PEOPLE Phase III Open-Label Extension Study Evaluating Viaskin Peanut in The Journal of Allergy and Clinical Immunology (DBV Technologies Press Release) - Jul 10, 2020 - P3, N=300; PEOPLE (NCT03013517); Sponsor: DBV Technologies; "Patients demonstrated durable, long-term clinical benefit with an additional two years of treatment with Viaskin™ Peanut (compound name DBV712 250 μg), with low discontinuations due to adverse events....These data from the largest long-term study of peanut allergy immunotherapy demonstrate continued treatment benefit of DBV712...Data from the PEOPLE trial demonstrate that DBV712 was associated with continued response over a three-year treatment period. 75.9% (107/141) saw an improvement in eliciting dose (ED) from baseline to Month 36....A favorable tolerability profile was observed with DBV712 in the PEOPLE trial..."
